Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when spread betting and/or trading CFDs with this provider. You should consider whether you understand how spread bets, CFDs, OTC options or any of our other products work and whether you can afford to take the high risk of losing your money.

69% of retail investor accounts lose money when spread betting and/or trading CFDs with this provider. You should consider whether you can afford to take the high risk of losing your money.

7 Top Stories

How Will China Respond to Trump’s Tariffs?

How Will China Respond to Trump’s Tariffs? 

China’s National People’s Congress kicked off yesterday and runs until March 11, shaping economic policy and spending plans. US President Donald Trump’s decision to double tariffs on Chinese imports will be a key focus, with domestic consumption likely to be a priority, Bloomberg reported. Investors interested in the recent, DeepSeek-led surge in Chinese tech stocks may be following the proceedings with interest. 

Record February for Foxconn

Foxconn [FXCOF] posted a 56.43% year-over-year revenue surge in February, reaching NT$551.38bn, a record for the month. The Apple [AAPL] supplier expects Q1 2025 performance to exceed the five-year average, with strong year-over-year growth. Revenue also rose 2.36% month-over-month. Foxconn, formally Hon Hai Precision [HNHAF], reports Q4 2024 results on March 14.

Musk vs. OpenAI

A US federal court rejected Elon Musk’s bid to halt OpenAI’s shift to a for-profit model but fast-tracked the broader trial to autumn. Musk claims OpenAI and Sam Altman abandoned the group’s original mission by prioritizing profits over public benefit. Judge Yvonne Gonzalez Rogers dismissed Musk’s injunction request, ruling that his arguments failed to justify the “extraordinary relief” sought, the Financial Times detailed.

These 3 Biotech Stocks Have Room to Grow 

As biotech stocks sink amid concerns over what RFK Jr.’s time as health secretary might mean for drug and vaccine development, there are plenty of opportunities in the biotech space. In this article OPTO unpacks three companies due to report Q4 results next week: BioNTech [BNTX], Legend Biotech [LEGN] and Protalix [PLX]. We discuss key growth drivers and identify potential headwinds in the months ahead.

Google vs. DOJ

Alphabet’s [GOOGL] Google is lobbying the Department of Justice (DOJ) to avoid being dismantled, Reutersreported. The DOJ is investigating Google for monopolistic practices in search and advertising. A spokesperson warned that proposed measures could harm the US economy and national security. The DOJ previously suggested Google might be forced to divest key assets like Chrome and Android.

Apple vs. UK

The tech giant has mounted a legal challenge to a UK government order to share encrypted user data, the BBC reported, appealing to the Investigatory Powers Tribunal. In January, the UK Home Office secretly demanded Apple provide access to encrypted data in national security cases. Instead of complying, Apple removed its strongest privacy tool, Advanced Data Protection, from the UK market. 

RIP CHIPS?

Having spoken against it during his election campaign, President Donald Trump has urged US lawmakers to repeal the 2022 bipartisan law that allocated $52.7bn in subsidies for semiconductor manufacturing, and redirect the funds toward debt repayment, according to ReutersLast month, OPTO outlined three chip stocks that could be well-placed to ride out the ongoing turmoil in the sector.

Disclaimer Past performance is not a reliable indicator of future results.

CMC Markets is an execution-only service provider. The material (whether or not it states any opinions) is for general information purposes only, and does not take into account your personal circumstances or objectives. Nothing in this material is (or should be considered to be) financial, investment or other advice on which reliance should be placed. No opinion given in the material constitutes a recommendation by CMC Markets or the author that any particular investment, security, transaction or investment strategy is suitable for any specific person.

The material has not been prepared in accordance with legal requirements designed to promote the independence of investment research. Although we are not specifically prevented from dealing before providing this material, we do not seek to take advantage of the material prior to its dissemination.

CMC Markets does not endorse or offer opinion on the trading strategies used by the author. Their trading strategies do not guarantee any return and CMC Markets shall not be held responsible for any loss that you may incur, either directly or indirectly, arising from any investment based on any information contained herein.

*Tax treatment depends on individual circumstances and can change or may differ in a jurisdiction other than the UK.

Continue reading for FREE

Latest articles